CR20110674A - Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST - Google Patents

Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST

Info

Publication number
CR20110674A
CR20110674A CR20110674A CR20110674A CR20110674A CR 20110674 A CR20110674 A CR 20110674A CR 20110674 A CR20110674 A CR 20110674A CR 20110674 A CR20110674 A CR 20110674A CR 20110674 A CR20110674 A CR 20110674A
Authority
CR
Costa Rica
Prior art keywords
patients
elevation
myocardial infarction
otamixaban
treatment
Prior art date
Application number
CR20110674A
Other languages
English (en)
Inventor
Jens Stechl
Angele Moryusef
Christophe Gaudin
Pascale Ythier-Moury
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20110674A publication Critical patent/CR20110674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al uso de éster metílico del ácido (2R, 3R)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico o una sal farmacéuticamente aceptable del mismo, para la preparación de un medicamento para su uso en el infarto de miocardio sin elevación del ST.
CR20110674A 2009-07-29 2011-12-15 Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST CR20110674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
EP10305192 2010-02-26

Publications (1)

Publication Number Publication Date
CR20110674A true CR20110674A (es) 2012-04-17

Family

ID=42542846

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110674A CR20110674A (es) 2009-07-29 2011-12-15 Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST

Country Status (25)

Country Link
US (1) US9492437B2 (es)
EP (1) EP2459193A1 (es)
JP (1) JP2013500298A (es)
KR (1) KR20120038982A (es)
CN (1) CN102470128A (es)
AR (1) AR077427A1 (es)
AU (1) AU2010277725B2 (es)
BR (1) BR112012001900A2 (es)
CA (1) CA2766533A1 (es)
CL (1) CL2012000196A1 (es)
CO (1) CO6491041A2 (es)
CR (1) CR20110674A (es)
DO (1) DOP2012000012A (es)
EC (1) ECSP12011627A (es)
IL (1) IL217612A (es)
MA (1) MA33455B1 (es)
MX (1) MX2012000457A (es)
NI (1) NI201200008A (es)
NZ (1) NZ597957A (es)
PE (1) PE20121401A1 (es)
RU (1) RU2542455C2 (es)
SG (1) SG177772A1 (es)
TW (1) TWI463982B (es)
UY (1) UY32807A (es)
WO (1) WO2011012527A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025572B1 (ru) * 2011-03-29 2017-01-30 Санофи Лекарственные формы отамиксабана с улучшенной стабильностью
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
AU2012234325B2 (en) 2011-03-29 2016-08-11 Sanofi Benzoic acid salt of Otamixaban
US9597322B2 (en) 2012-08-31 2017-03-21 Sanofi Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228355B1 (en) * 1996-01-02 2013-03-28 Aventis Pharma Inc Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
RU2225617C1 (ru) * 2002-12-16 2004-03-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st

Also Published As

Publication number Publication date
IL217612A (en) 2014-08-31
DOP2012000012A (es) 2012-02-15
PE20121401A1 (es) 2012-10-25
AR077427A1 (es) 2011-08-24
US9492437B2 (en) 2016-11-15
ECSP12011627A (es) 2012-02-29
CN102470128A (zh) 2012-05-23
SG177772A1 (en) 2012-03-29
TW201119655A (en) 2011-06-16
US20120238605A1 (en) 2012-09-20
WO2011012527A1 (en) 2011-02-03
BR112012001900A2 (pt) 2016-03-15
RU2542455C2 (ru) 2015-02-20
NI201200008A (es) 2012-05-29
CA2766533A1 (en) 2011-02-03
AU2010277725A1 (en) 2012-02-16
RU2012107483A (ru) 2013-09-10
MA33455B1 (fr) 2012-07-03
NZ597957A (en) 2014-05-30
AU2010277725B2 (en) 2016-08-18
JP2013500298A (ja) 2013-01-07
CL2012000196A1 (es) 2012-10-05
UY32807A (es) 2011-02-28
KR20120038982A (ko) 2012-04-24
CO6491041A2 (es) 2012-07-31
MX2012000457A (es) 2012-01-27
TWI463982B (zh) 2014-12-11
EP2459193A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2013003598A1 (es) Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CL2014001779A1 (es) Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201390799A1 (ru) Триазолопиридины
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
EA201270087A1 (ru) Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
CL2014000623A1 (es) Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades.
CL2011002522A1 (es) Compuestos derivados de (piran-) o (tiopiran-)quinazolinadiona, inhibidores de fosfodiesterasa 7 (pde7); procedimiento de preparacion; composicicion farmaceutica; y uso para tratar una enfermedad inflamatoria, inmunoinflamatoria, cardiovascular, del sistema nervioso central y/o periferico.